ESMO 2024: Treatment of uHCC - Episode 5

EMERALD-1 Study Results

, , , , ,

Panelists discuss the findings from the EMERALD-1 trial on durvalumab with or without bevacizumab combined with transarterial chemoembolization TACE for first-line treatment of unresectable hepatocellular carcinomaHCC, examining its implications on progression-free survival, safety, and outcomes based on baseline tumor burden.

Video content above is prompted by the following:

Dr Kudo: Please review the findings from the EMERALD-1 trial, assessing durvalumab ± plus or minus bevacizumab with transarterial chemoembolizationTACE in first-line1L treatment of uHCCunresectable hepatocellular carcinoma, and discuss the impact of these findings on the treatment landscape.
• 2024 American Society of Clinical Oncology (ASCO) GastroIintestinal Cancers Symposium: – PFS data (Lencioni et al., J Clin Oncol. LBA 432)
• 2024 ASCO Annual Meeting: – Ssafety analysis (Chan et al., J Clin Oncol. Abstract 4122)
• Outcomes by baseline tumor burden (Kudo, ESMO 2024 Congress, Poster Presentation 950P